Peringatan Keamanan

Symptoms of overdose include severe clumsiness or unsteadiness, severe drowsiness, severe dryness of mouth, nose, or throat, fast heartbeat, shortness of breath or troubled breathing, and warmth, dryness, and flushing of skin.

Profenamine

DB00392

small molecule approved

Deskripsi

Profenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.L46812 In the US, the marketing of profenamine has been discontinued.L46817

Struktur Molekul 2D

Berat 312.472
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1 to 2 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Well-absorbed from the gastrointestinal tract.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

681 Data
Aclidinium The risk or severity of adverse effects can be increased when Profenamine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Profenamine.
Mirabegron The risk or severity of urinary retention can be increased when Profenamine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Profenamine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Profenamine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Profenamine.
Tiotropium The risk or severity of adverse effects can be increased when Profenamine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Profenamine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Profenamine is combined with Umeclidinium.
Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Profenamine.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Profenamine.
Metoclopramide The therapeutic efficacy of Profenamine can be decreased when used in combination with Metoclopramide.
Glycopyrronium The risk or severity of adverse effects can be increased when Profenamine is combined with Glycopyrronium.
Memantine The risk or severity of adverse effects can be increased when Profenamine is combined with Memantine.
Dipyridamole The therapeutic efficacy of Profenamine can be decreased when used in combination with Dipyridamole.
Ephedrine Profenamine may increase the neuromuscular blocking activities of Ephedrine.
Clevidipine Profenamine may increase the neuromuscular blocking activities of Clevidipine.
Sar9, Met (O2)11-Substance P Profenamine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.
Moxisylyte Profenamine may increase the neuromuscular blocking activities of Moxisylyte.
Propacetamol Profenamine may increase the neuromuscular blocking activities of Propacetamol.
Procaine Profenamine may increase the neuromuscular blocking activities of Procaine.
Cocaine Profenamine may increase the neuromuscular blocking activities of Cocaine.
Trimethaphan Profenamine may increase the neuromuscular blocking activities of Trimethaphan.
Doxacurium Profenamine may increase the neuromuscular blocking activities of Doxacurium.
Chloroprocaine Profenamine may increase the neuromuscular blocking activities of Chloroprocaine.
Tubocurarine Profenamine may increase the neuromuscular blocking activities of Tubocurarine.
Bambuterol Profenamine may increase the neuromuscular blocking activities of Bambuterol.
Butyrylthiocholine Profenamine may increase the neuromuscular blocking activities of Butyrylthiocholine.
Oxybuprocaine Profenamine may increase the neuromuscular blocking activities of Oxybuprocaine.
Benzonatate Profenamine may increase the neuromuscular blocking activities of Benzonatate.
Succinylcholine The metabolism of Succinylcholine can be decreased when combined with Profenamine.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum toxin type A.
Glucagon Profenamine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Profenamine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Profenamine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Profenamine is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Profenamine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Profenamine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Profenamine is combined with Tramadol.
Methadone The risk or severity of adverse effects can be increased when Profenamine is combined with Methadone.
Levacetylmethadol The risk or severity of adverse effects can be increased when Profenamine is combined with Levacetylmethadol.
Morphine The risk or severity of adverse effects can be increased when Profenamine is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Profenamine is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Profenamine is combined with Hydromorphone.
Meperidine The risk or severity of adverse effects can be increased when Profenamine is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Profenamine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Profenamine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Profenamine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Profenamine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Profenamine is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Profenamine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Profenamine is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Profenamine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Profenamine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Profenamine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Profenamine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Profenamine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Profenamine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Profenamine is combined with Dezocine.
Methadyl acetate The risk or severity of adverse effects can be increased when Profenamine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Profenamine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Profenamine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Profenamine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Profenamine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Profenamine is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Profenamine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Profenamine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Profenamine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Profenamine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Profenamine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Profenamine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Profenamine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Profenamine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Profenamine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Profenamine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Profenamine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Profenamine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Profenamine is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Profenamine is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Profenamine is combined with Naloxegol.
Tropicamide The risk or severity of adverse effects can be increased when Profenamine is combined with Tropicamide.
Cyclopentolate The risk or severity of adverse effects can be increased when Profenamine is combined with Cyclopentolate.
Homatropine The risk or severity of adverse effects can be increased when Profenamine is combined with Homatropine.
Chlorphenoxamine The risk or severity of adverse effects can be increased when Profenamine is combined with Chlorphenoxamine.
Cimetropium The risk or severity of adverse effects can be increased when Profenamine is combined with Cimetropium.
Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Profenamine.
Chlorthalidone The serum concentration of Chlorthalidone can be increased when it is combined with Profenamine.
Bendroflumethiazide The serum concentration of Bendroflumethiazide can be increased when it is combined with Profenamine.
Metolazone The serum concentration of Metolazone can be increased when it is combined with Profenamine.
Benzthiazide The serum concentration of Benzthiazide can be increased when it is combined with Profenamine.
Hydroflumethiazide The serum concentration of Hydroflumethiazide can be increased when it is combined with Profenamine.
Indapamide The serum concentration of Indapamide can be increased when it is combined with Profenamine.

Target Protein

Histamine H1 receptor HRH1
Muscarinic acetylcholine receptor M1 CHRM1
Glutamate receptor ionotropic, NMDA 3A GRIN3A
Muscarinic acetylcholine receptor M2 CHRM2

Referensi & Sumber

Synthesis reference: Berg, S.S. and Ashley, J.N.; U.S. Patent 2,607,773; August 19,1952; assigned to Societe des Usines Chimiques Rhone-Poulenc, France.

Contoh Produk & Brand

Produk: 1 • International brands: 4
Produk
  • Parsitan 50
    Tablet • 50 mg • Oral • Canada • Approved
International Brands
  • Dibutil — Bayer
  • Parkin — Tanabe
  • Parsidol
  • Parsitan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul